Dec 16, 2019 7:00 am EST Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130
Nov 20, 2019 8:00 am EST Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients
Nov 18, 2019 8:00 am EST Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference
Nov 15, 2019 8:30 am EST Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update
Nov 11, 2019 7:00 am EST Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting
Nov 05, 2019 8:00 am EST Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment
Oct 24, 2019 9:00 am EDT Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting
Aug 14, 2019 7:00 am EDT Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update
Aug 12, 2019 7:00 am EDT Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110
Aug 07, 2019 11:15 am EDT Heat Biologics CEO and Lead Director to Participate in German Investor Forums